Company intelligence / Profile preview

Elion Health

New York, New York, United Stateselion.health ↗

Ownership: Private
Development stage: Commercial

Overview

Elion Therapeutics is developing SF001, a next-generation polyene antifungal rationally designed to reduce toxicity while maintaining efficacy against invasive fungal infections. The company has raised $81 million in Series B funding to advance SF001 through early-stage clinical trials. No published clinical results yet.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculePolyene antifungal
Industry: Biotech

Partnerships

AMR Action Fund

Beyond the preview

Go deeper on Elion Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elion Health.

Explore the full profile